Welcome to Nofinity

In this video, the speaker begins a structured 3-month self-experiment using a transcranial photobiomodulation device (Neuronic Light) to enhance brain function. The goal is to test the efficacy of near-infrared light (1070 nm) in crossing the blood-brain barrier.

Background and Technology

• Photobiomodulation uses light therapy to boost cellular energy production. The device emits near-infrared light at 1070 nm, which penetrates deeper into bone and tissue than shorter wavelengths.
• The mechanism: Light photons are absorbed by the cytochrome C oxidase enzyme in mitochondria, increasing ATP production. Concurrently, nitric oxide is released, improving blood flow and oxygen supply.

Study Protocol

• Duration: 12 weeks with daily sessions 6 days a week.
  • Morning: 10 minutes Glow protocol (100% intensity, continuous wave) for general cellular health, followed by 6 minutes Focus protocol (70%, 40 Hz pulse) for cognitive sharpness.
  • Evening: 9 minutes Peace protocol (20%, 10 Hz pulse) for relaxation.
• Measurements: Objective tests using Aura Ring (sleep quality, heart rate variability), Cambridge Brain Sciences (cognitive performance), and a homemade mood scale.

Expectations

• Month 1: Improvement in deep sleep stages and morning alertness.
• Month 2: Sharper focus and more stable mood.
• Month 3: Sustained energy, stable circadian rhythms, and better cognitive test scores.

Note: The speaker is an affiliate of the company but was not paid for the video. A detailed review will follow after the experiment.

Summary follows...

Summary follows...

Summary follows...

Summary follows...

• Otis, Kone, and Schindler are defensive elevator stocks benefiting more from servicing than new installations.
• The market grows 2.9% annually and could double over the next decade.

• Stock down 40% from its peak 1.5 years ago.
• P/E ratio: 19, Dividend yield: 2.48%, Market cap: $28 billion.
• Business model: Servicing 2.5 million elevators and escalators is the core, providing stable cash flows.
• Challenges: High debt from spin-off, negative equity, and weak new equipment sales in China.
• Financial health: Adjusted free cash flow of $1.5 billion, share buybacks of $800 million.
• Valuation: Intrinsic value at $43 (assuming 6% dividend growth); current price is higher. A margin of safety appears only at $30–35 (50% drop).
• Shareholder yield: Total yield of ~5% (2.5% dividend + 3% buyback yield).

• Kone: Better stock performance, focus on dividends (no massive buybacks). Solid balance sheet (near-zero debt). Adjusted free cash flow close to $2 billion.
• Schindler: Swiss company with confirmed guidance. Valuation similar to Kone.
• Common trends: Digitalization, connectivity, and modernization reduce maintenance costs and boost efficiency.
• Competition: Otis is market leader, followed by Kone and Schindler (oligopoly).

• Strengths: Stable, predictable cash flows, oligopolistic structure, growth tailwinds from urbanization in Asia.
• Weaknesses: High valuations in current market, insufficient margin of safety for value investors.
• Recommendation: Monitor these stocks; if prices drop (e.g., Otis to $30–35), they become attractive entry points.
• For patient investors: These defensive stocks offer dividend growth – but only at the right price.

Summary follows...